STOCK TITAN

Sonoma Pharmaceu - SNOA STOCK NEWS

Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.

Sonoma Pharmaceuticals, Inc. (SNOA) delivers innovative healthcare solutions through its patented Microcyn® technology, specializing in stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and animal health. This page provides a centralized resource for tracking the company’s latest developments, regulatory milestones, and strategic initiatives.

Access timely updates on FDA clearances, clinical study results, and product launches that demonstrate SNOA’s commitment to non-toxic, evidence-based therapies. Investors and healthcare professionals will find verified information about:

• New product approvals across global markets
• Partnership announcements with medical distributors
• Financial performance and growth strategies
• Research breakthroughs in HOCl applications

All content is curated to meet strict accuracy standards, with direct links to official press releases and validated third-party analyses. Bookmark this page for efficient monitoring of SNOA’s progress in advancing biocompatible wound care and antimicrobial solutions.

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the U.S. launch of its intraoperative pulse lavage irrigation treatment. The product, developed using Sonoma's Microcyn® Technology, replaces non-antimicrobial saline and aggressive rinsing solutions with a safe and effective solution that can prevent infection and improve healing time. The treatment is cost competitive with IV bags and can be used in a variety of surgical procedures. Sonoma is introducing the product at the Symposium on Advanced Wound Care Fall Conference in Las Vegas and expects it to be ready for commercial use in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the pricing of its public offering of 8,500,000 shares of common stock at $0.20 per share, expecting gross proceeds of approximately $1.7 million. The offering is set to close on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. announced financial results for its first fiscal quarter ended June 30, 2023. Revenue increased 6% compared to the same period last year, excluding a one-time event. Margins remained consistent year over year. Sonoma managed cash tightly, using only $0.3 million in its first fiscal quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
-
Rhea-AI Summary
Sonoma Pharmaceuticals announces the appointment of Dr. Hye Jin Chung to its Scientific Advisory Board. Dr. Chung's expertise in dermatology will contribute to the company's research and development efforts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
Rhea-AI Summary
Sonoma Pharmaceuticals announces a new application for its Microcyn® technology-based stabilized hypochlorous acid products. The intraoperative pulse lavage irrigation treatment can replace IV bags in surgical procedures, providing a non-toxic solution to prevent infection and improve healing time. The product is cost competitive with IV bags and is expected to be ready for commercial use in Europe in September 2023 and in the U.S. in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.33%
Tags
none
-
Rhea-AI Summary

Sonoma Pharmaceuticals has launched Podiacyn, an all-natural foot care product designed for over-the-counter use in the U.S. This product aims to manage foot odors, infections, and irritations while enhancing the body’s natural healing process. Podiacyn is clinically proven to eliminate bacteria and fungi, and its formulation is free of dyes, fragrances, and preservatives. The new product is available for consumers directly through their website and through third-party distributors. CEO Amy Trombly highlighted the opportunity in the growing global footcare market, which is expected to reach $5.4 billion by 2028, up from $3.7 billion in 2021. The launch reflects Sonoma's strategy to leverage its patented Microcyn technology, promoting foot health and hygiene.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq:SNOA) will showcase its Microcyn® technology-based products at the CPHI North America Conference in Philadelphia from April 25-27, 2023. The company aims to expand its distribution network in North America by attracting new partners and distributors. Attending this conference provides Sonoma with an opportunity to connect with pharmaceutical leaders and further grow its business through diversification of its product offerings. The company specializes in stabilized hypochlorous acid products for various applications, including wound and animal care, marketed in 55 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.26%
Tags
none
Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq:SNOA) and MicroSafe Group announced that their Nanocyn hospital-grade disinfectant has received new claims from the U.S. EPA effective against harmful pathogens including MRSA, Salmonella, and Norovirus. Additionally, Nanocyn earned the Green Seal Certification, highlighting its commitment to environmental health and sustainability. This disinfectant is already EPA-approved for various applications in healthcare and beyond. Expectations are set for commercialization by summer 2023. Both companies view these advancements as significant for enhancing product reliability and environmental responsibility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
Sonoma Pharmaceu

Nasdaq:SNOA

SNOA Rankings

SNOA Stock Data

3.72M
1.59M
1.25%
1.26%
0.6%
Drug Manufacturers - Specialty & Generic
Surgical & Medical Instruments & Apparatus
Link
United States
BOULDER